IFI-S · Mogroside V Series

Specimen SS-F-SWT-334 // SWEET · IFI-S

Mogroside V Series II-PR-B

Momordica grosvenorii

Monk Fruit

Tier IIMogroside V Series

Target Trait

2.88×

fold-change

Mogroside V yield fold-change

Technical Specifications

SKU

SS-F-SWT-334

Genomic Edits

5

GC Content

45.4%

Construct Length

3,240 bp

Promoter System

35S CaMV promoter

Expression System

PEG-mediated protoplast transfection

Host Strain

PEG/calcium transfection

Receptor Target

TAS1R2/TAS1R3

IFI Score

288

Pathway Edits

  • CYP87D18 overexpression for oxidative cyclization of 2,3-oxidosqualene to mogrol aglycone
  • UGT73A1 upregulation for the initial glucosylation step from mogrol to mogroside I
  • CYP450-M1 expression enhancement for oxidative functionalization during mogroside pathway
  • SQS squalene synthase upregulation for increased triterpenoid precursor squalene flux
  • SE squalene epoxidase activity enhancement for 2,3-oxidosqualene availability

Key Interventions

CYP87D18-mediated oxidative cyclization for mogrol aglycone biosynthesis in MomordicaUGT73A1-driven initial glucosylation establishing the mogroside glycosylation cascadeSQS and SE co-upregulation expanding triterpenoid precursor pool for mogroside V synthesis

IFI Subscale Profile

IFI Profile

IFI-S
288
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Enhanced performance variant: pilot-scale mogroside V production for ultra-high-intensity natural sweetener formulation trials with amplified TAS1R2/TAS1R3 receptor activation for premium-tier applications

License

$749 · Tier II License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?

Back to Sweet · IFI-SAll Modalities